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Mechanisms of Genomic Instabilities Underlying
Two Common Fragile-Site-Associated Loci,
PARK2 and DMD, in Germ Cell and Cancer Cell Lines
Jun Mitsui,1 Yuji Takahashi,1 Jun Goto,1 Hiroyuki Tomiyama,2 Shunpei Ishikawa,3 Hiroyo Yoshino,4
Narihiro Minami,5 David I. Smith,6 Suzanne Lesage,7 Hiroyuki Aburatani,8 Ichizo Nishino,5
Alexis Brice,7 Nobutaka Hattori,2 and Shoji Tsuji1,*
Common fragile sites (CFSs) are speciﬁc chromosome regions that exhibit an increased frequency of breaks when cells are exposed to
a DNA-replication inhibitor such as aphidicolin. PARK2 and DMD, the causative genes for autosomal-recessive juvenile Parkinsonism
and Duchenne and Becker muscular dystrophy, respectively, are two very large genes that are located within aphidicolin-induced
CFSs. Gross rearrangements within these two genes are frequently observed as the causative mutations for these diseases, and similar
alterations within the large fragile sites that surround these genes are frequently observed in cancer cells. To elucidate the molecular
mechanisms underlying this fragility, we performed a custom-designed high-density comparative genomic hybridization analysis to
determine the junction sequences of approximately 500 breakpoints in germ cell lines and cancer cell lines involving PARK2 or
DMD. The sequence signatures where these breakpoints occur share some similar features both in germ cell lines and in cancer cell lines.
Detailed analyses of these structures revealed that microhomologies are predominantly involved in rearrangement processes. Further-
more, breakpoint-clustering regions coincide with the latest-replicating region and with large nuclear-lamina-associated domains and
are ﬂanked by the highest-ﬂexibility peaks and R/G band boundaries, suggesting that factors affecting replication timing collectively
contribute to the vulnerability for rearrangement in both germ cell and somatic cell lines.Introduction
Common fragile sites (CFSs) are speciﬁc chromosome
regions that exhibit an increased frequency of gaps or
breaks when cells are exposed to a DNA replication
inhibitor such as aphidicolin. CFSs are well known to be
predisposed to breakages and rearrangements, particularly
in cancer cells. Recently, it was reported that aphidicolin-
mediated replication stress could induce large submicro-
scopic deletions at CFSs in a human-mouse cell-hybrid
system.1 Many of the aphidicolin-induced CFSs have been
found to span extremely large genes, including PARK2
(MIM 602544), DMD (MIM 300377), FHIT (MIM 601153),
WWOX (MIM 605131), GRID2 (MIM 602368), LARGE
(MIM 603590), CTNNA3 (MIM 607667), NBEA (MIM
604889), and CNTNAP2 (MIM 604569).2 Intriguingly,
PARK2 and DMD are both genes responsible for human
hereditary diseases, and gross deletions are frequently
observed as the causative germline mutations.
PARK2 (chromosome 6: 161,688,580–163,068,824, NCBI
build 36.1), encompassing 1.4 Mb, which is embedded in
a CFS (FRA6E), is the gene responsible for autosomal-reces-
sive juvenile Parkinsonism (AR-JP [MIM 600116]).3 Among
various causative germline mutations in PARK2, gross dele-
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Thtions,4 with the deletion hotspots clustering in exons 3
and 4.5 As the consequence of the localization of PARK2
in FRA6E, PARK2 is also frequently targeted by deletions
in various cancer cells.6 DMD (chromosome X: 31,047,
266–33,139,594), which is also embedded in a CFS
(FRAXC),7 encompasses 2.1Mb and is the gene responsible
for Duchenne and Becker muscular dystrophy (DMD and
BMD [MIM 310200 and 300376]).8 Similarly to PARK2,
DMD is also frequently targeted by gross deletions in
patients with DMD or BMD (hereafter DMD/BMD) and in
thosewith various cancers.7,9 Approximately 60%of causa-
tive germline mutations are gross deletions, and deletion
hotspots are in exons 45 to 52.10 Although it has not drawn
muchattention, the frequent occurrence of gross rearrange-
ments in the genomic regions corresponding to CFSs in
patients with AR-JP or DMD/BMD suggests that a common
basis underlies the frequent occurrence of rearrangements
in both germ cell and somatic cell lines. CFSs are chromo-
somal regions that are particularly sensitive to certain forms
of replication stress, and there are lines of evidence suggest-
ing that CFSs represent unreplicated DNA resulting from
stalled replication forks.11,12 These sites replicate lateduring
the S phase, evenundernormal culture conditions.13,14 The
context of the nucleotide sequences and/or chromosomal
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however, has not been well understood. Furthermore,
molecular mechanisms responsible for clustering of the
breakpoints at these CFSs and those underlying the repair
processes of the breakpoints remain to be elucidated.
To explore why these particular genomic regions are
prone to rearrangements in germ cells and cancer cells, it
is essential to determine the precise positions of the break-
point-clustering regions and to analyze the junction-
sequence signatures in detail. Determination of junction
sequences, however, has been extremely laborious by
conventional methods, such as the PCR-based genome-
walking method, particularly in the case of large-size rear-
rangements. To date, only a few breakpoints involving
PARK2 and DMD have been determined at the nucleotide
level in either germ cell or somatic cell mutations.5,15–19
To accomplish an efﬁcient determination of rearrange-
ment breakpoints at the nucleotide level, we have
applied a custom-designed high-density array comparative
genomic hybridization (array CGH) system, which enabled
us to determine approximately 500 breakpoints in patients
with AR-JP and DMD/BMD as well as in cancer cell lines.
We herein elucidated the clustering of the breakpoints
and the sequence signatures at the breakpoint junctions
in germ cell and somatic cell mutations in these CFSs.
This gives insights into the mechanisms of chromosomal
fragility within the CFSs.Material and Methods
Materials
For the determination of rearrangement breakpoints in the germ-
line mutations of PARK2 or DMD, we enrolled 206 unrelated
patients with AR-JP and 208 unrelated male patients with DMD/
BMD. The patients with AR-JP were from multiple ethnicities,
including 113 Japanese, 15 East Asians, 64 Europeans,20,21 and
14 others, with one or two rearranged PARK2 alleles that have
been identiﬁed by PCR-based gene-dosage analysis or multiplex
ligation-dependent probe ampliﬁcation (MLPA) analysis. All of
the patients with DMD/BMD were males from the Japanese popu-
lation, with hemizygous deletions or duplications in DMD that
have been identiﬁed by multiplex PCR analysis or MLPA analysis.
For the determination of rearrangement breakpoints in the
somatic cell mutations of PARK2 and DMD, we analyzed 125
cancer cell lines obtained from the American Type Culture Collec-
tion (ATCC) and the laboratories of D.I.S. or H.A., including 41
gastrointestinal tract cancer cell lines, 26 breast cancer cell lines,
24 urogenital tract cancer cell lines, 14 respiratory tract cancer
cell lines, 9 skin cancer cell lines, 7 brain cancer cell lines, and 4
hematological malignancy cell lines (the cancer cell line list is
available in Table S1, available online). This study was approved
by the institutional review boards of all of the participating
institutions.Array CGH Analysis
High-density microarrays that contain 35,668 probes covering the
entire PARK2 gene (chromosome 6: 161,500,000–163,500,000),
with an average probe interval of 112 bp, or 40,632 probes that
cover the entire DMD gene (chromosome X: 31,000,000–76 The American Journal of Human Genetics 87, 75–89, July 9, 201033,500,000), with an average probe interval of 82 bp, were
designed on the Agilent platform. The probes were designed by
a laboratory-made program (programmed by S.T.), CGH probe
version 4.1 (available on request), and were 60-mer oligonucleo-
tides with GC contents ranging from 31% to 39%.We also avoided
repetitive sequences.22 For those regions where the probes could
not be designed with GC contents between 31% and 39% at
appropriate probe intervals, the probes were designed with shorter
lengths (45 to 60 oligonucleotides) depending on the GC content,
so that their optimal hybridization temperature was close to
longer oligonucleotide probes utilized. A single control sample
was used for all of the subjects in CGH analysis of PARK2, and
a male control sample was used for CGH analysis of DMD.
Genomic DNAs were hybridized to the microarrays, followed by
scan and analysis using Agilent CGH Analytics software version
4.0.76 (Agilent Technologies, CA, USA). For determining each
breakpoint at the nucleotide level, a pair of oligonucleotide
primers was designed to amplify each segment across the break-
point junction. Ampliﬁed junction fragments were subjected to
direct nucleotide-sequence analysis utilizing an ABI 3100 Genetic
Analyzer (Life Technologies, CA, USA). The data on rearrange-
ments of this study are accessible in the NCBI Database of
Genomic Structural Variation (dbVAR); the public accession
number is nstd36.Nucleotide-Sequence Analysis
The positions of nucleotide sequences described in this study were
based on the human reference sequence of NCBI build 36 version
1. The nucleotide sequences encompassing the breakpoints were
subjected to many different computational analyses. The FASTN
program of GENETYX version 9.0.6 software (Genetyx, Tokyo,
Japan) was used to calculate the amount of sequence homology
between the nucleotide sequences encompassing two breakpoints.
To investigate the sequence characteristics of the junctions of rear-
rangements, we searched for extended homologies between the
pairs of nucleotide sequences encompassing the breakpoints
(100 bp upstream and 100 bp downstream). The RepeatMasker
program was used to evaluate interspersed repeat-element con-
tent. Origins of inserted sequences at the junctions were deter-
mined by the BLAST program and SSEARCH program against the
entire human genome. DNA Pattern Find was used for detecting
sequence motifs that were abundant at deletion breakpoints.23
High-ﬂexibility regions were identiﬁed with the TwistFlex
program, which assesses DNA ﬂexibility by measuring the local
potential variation in the DNA structure at a twist angle of DNA,
and the ﬂexibility parameter is expressed as the ﬂuctuation of
this angle.24 All of these programs were used with default settings.
The positions of the chromosomal R/G band25 and nuclear-
lamina-associated domains (LADs)26 were retrieved from the
UCSC Genome Browser (NCBI build 36.1). The replication-timing
map of chromosome 6 was retrieved from a previous report, as
determined by array CGH analyses of S phase DNA to G1 phase
DNA.27 The sex-averaged recombination rate was obtained from
the deCODE recombination map.28Statistical Methods
All statistical analyses were performed by means of StatsDirect
statistical software version2.6.5 (StatsDirect, UK).Means,medians,
variances, skewness, and kurtosis were determined for the distribu-
tions of breakpoints at PARK2 and DMD loci, in patients and
in cancer cell lines. Differences between the mean breakpoint
positions in patients and in cancer cell lines were analyzed by
means of theMann-Whitney U test. Differences between the stan-
dard deviations of breakpoint positions in patients and in cancer
cell lines were analyzed by means of the squared-ranks test. The
null hypothesis was rejected at p < 0.05.Results
Determination of Breakpoints at the Nucleotide Level
on the Basis of Custom-Designed Array CGH Analyses
To characterize the breakpoints in PARK2 andDMD located
at CFS, we have applied a locus-speciﬁc high-density array
CGH analysis system to 206 patients with AR-JP, 208 male
patients with DMD/BMD, and 125 cancer cell lines. Repre-
sentative cases of AR-JP with a deletion in PARK2 (Figures
1A–1D) and a case of AR-JP with a duplication in PARK2
(Figures 1E–1G) are shown. Array CGH analyses easily
enabled detection of a deletion or a duplication, as shown
in Figure 1A or 1E, respectively. For determination of the
nucleotide sequences at the deletion breakpoints, a pair
of PCR primers ﬂanking the deletion was designed to
obtain junction fragments by PCR (Figure 1C). When the
PCR products containing the junction segment were
obtained (Figure 1B), the nucleotide sequences were easily
determined by direct nucleotide-sequence analysis of the
PCR products (Figure 1D). For determination of the nucle-
otide sequences of duplication breakpoints, three pairs of
PCR primers were designed, based on the head-to-tail,
head-to-head, and tail-to-tail models (Figure 1F). When
the PCR products were obtained for either of these conﬁg-
urations (Figure 1G), the nucleotide sequences were deter-
mined as described above.
We then applied these methods to determine the
breakpoints of PARK2 at the nucleotide-sequence level in
patients with AR-JP. For this purpose, we selected patients
with AR-JP who had previously been determined to have
one or two rearranged PARK2 alleles on the basis of PCR-
based gene-dosage analysis or MLPA analysis. In array
CGH analyses of PARK2 of 206 patients with AR-JP, 268
exonic rearrangements (243 deletions and 25 duplications)
and ﬁve intronic deletions were detected. Nucleotide
sequences of the 252 breakpoint junctions (92.3%) were
determined, including 235 deletions (94.8%) and 17
duplications (68.0%). In total, 62 had homozygous exonic
rearrangements, 57 had compound-heterozygous exonic
rearrangements, and 69 had a heterozygous exonic rear-
rangement. In contrast to the results obtained by the
PCR-based gene-dosage or MLPA analysis, exonic rear-
rangements were not detected by the array CGH analysis
in 18 patients with AR-JP, raising the possibility that the
PCR-based conventional analyses may provide false posi-
tive results. For comparison of the breakpoints of PARK2
in the germline mutations in patients with AR-JP, we
then conducted similar array CGH analyses of PARK2 in
125 cancer-derived cell lines and identiﬁed 42 rearrange-
ments (39 deletions and three duplications) in 28 of the
cancer cell lines (22.4%). The nucleotide sequences of theTh41 breakpoint junctions (97.6%), including 39 deletions
(100.0%) and two duplications (66.7%), were determined.
Because ten deletions and two duplications were found
among multiple cancer cell lines, 32 independent break-
points (31 deletions and one duplication) were deter-
mined. Among 32 independent breakpoints, two (one
deletion and one duplication) were also found in patients
with AR-JP, raising the possibility that they were derived
from germ cell lines or that the identical rearrangements
of germ cell lines independently occurred in somatic cell
lines. Intriguingly, in one cancer cell line (COLO320), six
independent deletions were observed simultaneously
(Figure S1).
To compare the breakpoint clustering and the signatures
of the breakpoint-junction sequences of PARK2 (FRA6E)
with those at other CFSs, we further conducted array
CGH analyses of DMD, which is embedded in another
CFS, FRAXC,7 in 208 patients with DMD/BMD. All of the
patients had hemizygous rearrangements (172 deletions
and 36 duplications) involving exons, but three intronic
deletions were also identiﬁed. We were able to determine
nucleotide sequences of 197 breakpoint junctions (93.4%),
including 167 deletions (95.4%) and 30 duplications
(83.3%). None of the breakpoints determined occurred at
the same exact position. We subsequently conducted
similar array CGH analyses ofDMD in the same 125 cancer
cell lines. This analysis identiﬁed nine rearrangements
(eight deletions and one duplication) in the seven cancer
cell lines (5.6%) and determined the nucleotide sequences
of six breakpoint junctions (66.7%), including six dele-
tions (75.0%). Although most of the breakpoints demon-
strated by the array CGH were identiﬁed at the nucleotide
level, several breakpoints were not able to be determined.
This included 13 of the 248 deletions and eight of the 25
duplications in PARK2 in patients with AR-JP, one of the
two duplications in PARK2 in cancer cell lines, eight of
the 175 deletions and six of the 36 duplications in DMD
in patients with DMD/BMD, and two of the eight deletions
and the one duplication in DMD in cancer cell lines. For
three deletions in patients with DMD/BMD, breakpoints
located outside the region covered by the designed array
were not identiﬁed. With the exception of these large
deletions, the reasons of failed breakpoint identiﬁcation
were not certain. It could be due to the complex structures
of rearrangements, such as a deletion coupled with an
inversion, or the insertion of the duplicated sequence in
a nontandem site, which were difﬁcult to amplify by the
strategies shown in Figures 1C and 1F.
The results of the array CGH analyses and determination
of breakpoints at the nucleotide level are shown in Tables
S2A–S2G and are summarized in Table 1. It should be
noted that the frequencies of rearrangements in PARK2
and DMD observed in cancer cell lines were quite high
(42 rearrangements in 125 cancer cell lines in PARK2 and
nine rearrangements in 125 cancer cell lines in DMD), sup-
porting the instability of CFS-associated loci in cancer cell
lines. Nucleotide positions of the breakpoints are deﬁnede American Journal of Human Genetics 87, 75–89, July 9, 2010 77
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Figure 1. Determination of Breakpoint-Junction Sequences in PARK2 by Custom-Designed High-Density Array CGH Analysis
(A) Scan data of array CGH analysis of a patient with AR-JP with 82 kb homozygous deletions (exon 4 of PARK2). The horizontal axis
represents the nucleotide position. The vertical axis represents log2 (ratio of case to reference signal intensities on array CGH). Dots
of log2 (ratio of case to reference signal intensities) larger than 0 are shown in red, and those smaller than 0 are shown in green. The
physical map of PARK2 is also shown above the scan data.
(B) Agarose gel electrophoresis of PCR products derived from the patient’s genomic DNA obtained by employing primer pairs ﬂanking
the deletion. Ampliﬁcations did not occur in normal alleles because the segment between primers was too large (82 kb), while the band
corresponding to the PCR products of 520 bp derived from the deletion allele was clearly visualized.
(C) Design of primer pairs for speciﬁc ampliﬁcation of the deletion allele by PCR. A pair of oligonucleotide primers (denoted by red and
blue arrows) was designed to amplify the segment across the breakpoint junction.
(D) Electropherogramof ampliﬁed segment encompassing breakpoint junctions. The nucleotide sequence corresponding to the segment
upstream of the deletion is shown in blue, and the sequence corresponding to the segment downstream of the deletion is shown in red.
The underlined inserted sequence not identical to either the upstream or the downstream segment is shown in black.
(E) Scan data of array CGH analysis of a patient with AR-JP with a homozygous duplication (exons 6 of PARK2) that turned out to be
a tandem duplication. The horizontal axis represents the nucleotide position. The vertical axis represents log2 (ratio of case to reference
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Table 1. Numbers of Rearrangements Determined by Array CGHAnalyses and Those of Breakpoints Determined at Nucleotide Levels along
with Numbers of Recurrently and Nonrecurrently Observed Breakpoints
Locus
Sample
Sources
No. of
Samples
Breakpoints Determined at Nucleotide Levelb
Rearrangements
Detected
by Array CGHa
Total No. of Breakpoints
Determined
at Nucleotide Level Recurrently Observedc
Not Recurrently
Observedd
Total Deletion Duplication Total Deletion Duplication Total Deletion Duplication Total Deletion Duplication
PARK2 Patients
with
AR-JP
206 273 248 25 252 235 17 22 [112] 20 [107] 2 [5] 140 128 12
Cancer
cell
lines
125 42 39 3 41 39 2 4 [12] 3 [10] 1 [2] 28 28 0
DMD Patients
with
DMD/
BMD
208 211 175 36 197 167 30 0 [0] 0 [0] 0 [0] 197 167 30
Cancer
cell
lines
125 9 8 1 6 6 0 0 [0] 0 [0] 0 [0] 6 6 0
a Number of rearrangements demonstrated by array CGH.
b Number of rearrangements determined at the nucleotide level.
c Number of independent rearrangements observed in multiple cases. Number in bracket is the number of total recurrently observed rearrangements.
d Number of independent rearrangements observed individually.as shown in Figure S2. All the duplications of PARK2 and
DMDwere tandem duplications, and inverted duplications
were not found among the samples in this study. Deletions
were more frequently observed than duplications. The
ratios of deletions to duplications detected by the array
CGH analyses were 9.9 in PARK2 in patients with AR-JP,
13.0 in PARK2 in cancer cell lines, 4.9 in DMD in patients
with DMD/BMD, and 8.0 in DMD in cancer cell lines.Multiple Independent Rearrangements Had
Frequently Occurred in PARK2 and DMD
The results that 140 of the 252 breakpoints (55.6%) in
PARK2 in patients with AR-JP were distinct (Table 1) indi-
cated that recurrent mutations are less frequent than
nonrecurrent mutations. This notion is further strength-
ened by the observation that all of the 192 breakpoints
in DMD in patients with DMD/BMD are independent
without any identical junctions. Taken altogether, this
indicates that multiple independent rearrangements had
frequently occurred in PARK2 and DMD. Although the
number of cases is limited, there were 22 recurrently
observed breakpoints in PARK2 in patients with AR-JP,
and the most frequently observed breakpoint (recurrently
observed breakpoint no. 1) was present in 22 index
patients from different ethnic populations (eight weresignal intensities on array CGH). Dots of log2 (ratio of case to refere
smaller than 0 are shown in green.
(F) Design of primer pairs for speciﬁc ampliﬁcation of the duplicated
models. Oligonucleotide primers are denoted by red and blue arrows
(G) Agarose gel electrophoresis of the PCR products derived from pat
duplicated segment. The PCR products are generated only when app
DNA segments.
Thobserved in Asians and 14 in Europeans), and the other
21 recurrently observed breakpoints were found only in
a single ethnic population (Table 2). The signatures of
the junction sequences are described later in detail.Breakpoints Are Clustered in Speciﬁc Genomic
Regions in Germ Cell Mutations
The histogram and cumulative-frequency distribution of
the positions of breakpoints showed that the breakpoints
were obviously clustered at speciﬁc genomic regions in
PARK2 and DMD in germ cell lines (Figures 2A and 2B).
The breakpoint-clustering region in PARK2 in patients
with AR-JP closely coincided with the previously reported
region in FRA6E prone to DNA double-strand breaks,
which has been referred as to the center of FRA6E
(Figure 2D).5 Furthermore, the breakpoint-clustering
region inDMD in patients with DMD/BMDwas embedded
in FRAXC (Figure 2D).7 These ﬁndings of breakpoint clus-
tering in PARK2 and DMD in germ cell lines were consis-
tent with the previous studies that had identiﬁed deletion
hotspots in exons 3 and 4 of PARK2 in patients with AR-JP5
and in exons 45–52 of DMD in patients with DMD/BMD
(Figure 2).10 The breakpoint distributions in PARK2 and
DMD in cancer cell lines seemed to be more dispersed
than those observed in germ cell lines. To assess differencesnce signal intensities) larger than 0 are shown in red, and those
allele by PCR based on head-to-tail, head-to-head, and tail-to-tail
.
ient’s genomic DNA obtained by employing primer pairs ﬂanking
ropriate primers are used for ampliﬁcation of rearranged genomic
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Table 2. List of Recurrently Observed Breakpoints in PARK2 in Patients with AR-JP
No.
No. of
Index
Patients Hom. Het.
Del. or
Dup. Origin Upstream
Identical
Sequence
Inserted
Sequence Downstream
Exon or
Intron
Extended
Homology
1 22 1 21 deletion 8 Asia and
14 Europe
162,506,819 GATTACAGGCA
TGAGCCACC
- 162,503,759 intron 4 Alu (311 bp)/Alu
(307 bp)
2 19 9 10 deletion Asia 162,567,759 - GAG 162,486,065 exon 4
3 9 2 7 deletion Japan 162,857,698 TTC - 162,494,729 exons 2–4
4 8 1 7 deletion Asia 162,660,297 - TAAAACTG 162,658,014 intron 2
5 7 5 2 deletion Japan 162,333,460 A - 162,126,458 exons 6–7
6 6 4 2 deletion Asia 162,612,866 - CACAAATATC
ACAAATATC
162,489,437 exons 3–4
7 5 1 4 deletion Japan 162,653,100 TATTT - 162,510,558 exons 3–4
8 3 0 3 deletion Asia 162,189,426 TAAG - 162,085,168 exon 7
9 3 0 3 deletion France 162,547,125 AGCAC - 162,536,937 exon 4
10 3 1 2 deletion Asia 162,571,209 - TATATAC 162,225,376 exons 4–6
11 3 0 3 deletion Japan 162,647,230 T - 162,591,063 exon 3
12 3 2 1 deletion Japan 162,697,743 - - 162,502,832 exons 3–4
13 3 2 1 duplication Japan 162,359,815 - T 162,288,602 exon 6
14 2 0 2 deletion Vietnam 162,461,205 AAAAATA - 162,365,391 exon 5 Alu (267 bp)/Alu
(302 bp)
15 2 0 2 deletion Japan 162,543,628 - T 162,519,459 exon 4
16 2 1 1 deletion Japan 162,561,255 CTTC - 162,508,229 exon 4
17 2 1 1 deletion Europe 162,608,217 CT - 162,548,381 exon 3
18 2 1 1 deletion Japan 162,615,492 AGG - 162,555,347 exon 3
19 2 0 2 deletion Korea 162,623,148 - AA 162,569,292 exon 3
20 2 0 2 deletion France 162,630,240 GAT - 162,288,742 exons 3–6
21 2 1 1 deletion Japan 162,840,504 C - 162,735,373 exon 2
22 2 0 2 duplication France 162,835,997 - T 162,637,347 exon 2
Abbreviations are as follows: Hom., homozygous; Het., heterozygous; Del., deletion; Dup., duplication.and similarities of the breakpoint distributions between
germ cell lines and cancer cell lines, statistical data
including mean, median, standard deviation, skewness,
and kurtosis of breakpoint positions were calculated
(Table 3). It was found that the differences in mean and/or
median breakpoint positions between germ cell lines and
cancer cell lines were relatively small (within 20–90 kb),
with no signiﬁcant differences detected via the Mann-
Whitney U test. The differences in standard deviation of
breakpoint positions in cancer cell lines were relatively
larger than those in germ cell lines. The squared-ranks
equality-of-variance test revealed that differences in vari-
ance across germ cell and cancer cell lines in PARK2 was
signiﬁcant, whereas that in DMD was not signiﬁcant,
possibly due to the small sample size of somatic rearrange-
ments in DMD. Taken together, the center of breakpoint
distribution in PARK2 and DMD may be similar in germ
cell and cancer cell lines, but the variance of distribution
may be larger in cancer cell lines than that in germ cell80 The American Journal of Human Genetics 87, 75–89, July 9, 2010lines. Possible explanations of the difference are that the
sample selections for patients with AR-JP and with DMD/
BMD biased the breakpoint distributions and that the
cancer cell lines tended to generate larger rearrangements
in these loci as a result of increased genomic instability.
The Database of Genomic Variants (accessed in March
2010)29 included 48 and 6 copy-number variations
(CNVs) (more than 1 kb in length) in the regions in
PARK2 (chromosome 6: 161,500,000–163,500,000) and
in DMD (chromosome X: 31,000,000–33,500,000), respec-
tively. The distributions of these breakpoints in PARK2
showed similarities with those observed in patients with
AR-JP (Figures 2B and 2C).
Junction-Sequence Signatures in Germ Cell
and Somatic Cell Mutations
On the basis of the sequences ﬂanking the breakpoints, the
junction-sequence signatures were analyzed and then clas-
siﬁed into three groups: (1) junctions with extended
PARK2
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Figure 2. Histograms and Cumulative-Frequency Distributions
of Breakpoint Positions
(A) Histograms of breakpoint positions in PARK2 in AR-JP patients
or cancer cell lines, and in DMD in patients with DMD/BMD or
cancer cell lines. The horizontal axis represents nucleotide posi-
tions, and the vertical axis represents the number of breakpoints.
The numbers of the positions of the upstream (toward the tran-
scriptional initiation site) breakpoints are shown in white, and
those of the downstream breakpoints are shown in black.
(B) Cumulative-frequency distributions of breakpoint positions in
PARK2 in patients with AR-JP or cancer cell lines, and those in
DMD in patients with DMD/BMD or cancer cell lines: The hori-
zontal axis represents the nucleotide positions of breakpoints.
The vertical axis represents cumulative frequencies of breakpoints.
The upstream breakpoints are shown in white, and the down-
stream breakpoints are shown in black.
(C) Cumulative frequency distributions of breakpoint positions
(PARK2 and DMD) in control subjects obtained from the Database
of Genomic Variants. Physical maps of PARK2 and DMD, along
with schematic representations of the center of FRA6E and
FRAXC, are shown below.homologies, (2) junctions with microhomologies, and (3)
junctions without extended homologies or microhomolo-
gies (Table 4). An extended homology was detected via
the FASTN program with an optimum score R 300 by
comparing the pairs of 200 bp nucleotide sequences
encompassing the breakpoint junctions (100 bp upstream
and 100 bp downstream). In this study, we refer to suchThshort stretches of identical sequences (% 8 bp) at break-
point junctions as microhomologies.
Search for extended homologies revealed that seven of
the 162 junctions (4.3%) in PARK2 in patients with AR-JP,
one of the 32 junctions (3.1%) in PARK2 in cancer cell lines
(identical to one of the seven junctions observed in patients
with AR-JP), two of the 197 junctions (1.0%) in DMD in
patients with DMD/BMD, and none of the six junctions
(0.0%) in DMD in cancer cell lines had junctions with
extendedhomologies (Table 4), all ofwhichwere embedded
in the same repetitive sequences: seven Alu/Alu sequences
in PARK2 (two were recurrently observed), and one Alu/
Alu sequence and one L1/L1 sequence in DMD. Among
these nine junctions with extended homologies, seven
had identical sequences of 92 bp (L1P1 and L1P1), 28 bp
(AluJb and AluSx), 20 bp (AluSq/x and AluSg), 18 bp
(AluSq/x and AluY), 15 bp (AluSc and AluSg/x), 8 bp (AluY
and AluSg/x), and 7 bp (AluJb and AluSx) ﬂanking the junc-
tions, resulting in formation of completely chimeric L1/L1
or Alu/Alu sequences. The remaining two formed partially
chimeric Alu/Alu with inserted sequences of 7 bp (AluSg/x
and AluSg/x) and 12 bp (AluYand AluSq) at their junctions
(Figure S3). Intriguingly, the majority of the junctions were
frequently associatedwithmicrohomologies (1–8 bp): 97 of
the 162 junctions (59.9%) in PARK2 in patients with AR-JP,
19 of the 32 junctions (59.4%) in PARK2 in cancer cell lines,
128 of the 197 junctions (65.0%) in patients with DMD/
BMD in DMD, and three of the six junctions (50.0%) in
DMD in cancer cell lines hadmicrohomologies at junctions
(Table 4). Note that frequencies of microhomologies were
markedly similar between PARK2 and DMD and also
between germ cell lines and cancer cell lines. Regarding
the junctions without extended homologies or microho-
mologies, it was revealed that 58 of the 162 junctions
(35.8%) in PARK2 in patients with AR-JP, 12 of the 32 junc-
tions (37.5%) in PARK2 in cancer cell lines, 67 of the 197
junctions (34.0%) in DMD in patients with DMD/BMD,
and three of the six junctions (50.0%) in DMD in cancer
cell lines were without extended homologies or identical
sequences (Table 4). Among these, 51 of the 162 junctions
(31.5%) in PARK2 in patients with AR-JP, eight of the 32
junctions (25.0%) in PARK2 in cancer cell lines, 51 of the
197 junctions (25.9%) in DMD in patients with DMD/
BMD, and two of the six junctions (33.3%) in DMD in
cancer cell lines had inserted sequences. We found that
four junctions in PARK2 in patients with AR-JP, two junc-
tions in PARK2 in cancer cell lines, and two junctions in
DMD in patients with DMD/BMD had inserted sequences
of more than 19 bp, whose origins were searched by the
BLAST program and SSEARCH programs. It was revealed
that two inserted sequences in PARK2 deletions in cancer
cell lines and one inserted sequence in DMD deletion in
patients with DMD/BMD originated from repetitive
sequences (two Alu and one THE1B), which correspond to
‘‘67–112 bp of Alu,’’ ‘‘10–30 bp of Alu,’’ and ‘‘83–332 bp of
THE1B’’ (Figure S4). The origins of the other inserted
sequences remained undetermined.e American Journal of Human Genetics 87, 75–89, July 9, 2010 81
Table 3. Distribution of Breakpoint Positions in Germ Cell Lines and in Cancer Cell Lines
Loci Breakpoints Samples Number Mean Median
Mann-
Whitney
U test
Standard
Deviation
Squared-
Ranks
Test Skewness Kurtosis
PARK2 upstream
breakpoints
patients with
AR-JP
162 162,632,436 162,648,608 p ¼ 0.36 203,951 p < 0.0001 1.21 4.01
cancer cell lines 32 162,549,884 162,626,524 401,285 0.30 0.37
downstream
breakpoints
patients with
AR-JP
162 162,462,592 162,515,588 p ¼ 0.53 210,775 p < 0.0001 1.35 3.03
cancer cell lines 32 162,405,816 162,440,014 389,800 0.38 0.56
DMD upstream
breakpoints
patients with
DMD/BMD
197 32,151,340 31,967,332 p ¼ 0.49 405,283 p ¼ 0.99 0.73 0.93
cancer cell lines 6 32,063,805 31,932,249 518,968 1.57 2.75
downstream
breakpoints
patients with
DMD/BMD
197 31,969,561 31,796,456 p ¼ 0.78 402,560 p ¼ 0.81 0.80 0.71
cancer cell lines 6 31,900,988 31,816,981 600,593 1.12 2.25Among the22 recurrentlyobservedbreakpoints inPARK2
in patients with AR-JP (Table 2), two junctions (9.1%) had
extended homologies. One (recurrently observed break-
point no. 1) was the most frequent and was observed in
multiple ethnicities. The other breakpoint (recurrently
observed breakpoint no. 14) was found in two patients
from Vietnam. These two breakpoints were embedded inTable 4. Junction-Sequence Signatures
PARK2 (Germ Cell Lines) PARK2 (Cancer C
N % N %
Junctions with Extended Homologies
Total 7 4.3% 1 3.1
Junctions with Microhomologies (Identical Sequences% 8 bp)
R 9 bp identical sequences 0 0.0% 0 0.0
8 bp identical sequences 1 0.6% 0 0.0
7 bp identical sequences 1 0.6% 1 3.1
6 bp identical sequences 1 0.6% 0 0.0
5 bp identical sequences 8 4.9% 1 3.1
4 bp identical sequences 9 5.6% 5 15.
3 bp identical sequences 23 14.2% 4 12.
2 bp identical sequences 26 16.0% 3 9.4
1 bp identical sequences 28 17.3% 5 15.
Total 97 59.9% 19 59.
Junctions without Extended Homologies or Microhomologies
Insertions of repetitive
sequences
0 0.0% 2 6.3
Insertions of sequences
of undetermined origin
51 31.5% 8 25.
No insertions 7 4.3% 2 6.3
Total 58 35.8% 12 37.
82 The American Journal of Human Genetics 87, 75–89, July 9, 2010the same Alu sequences (approximately 300 bp in length),
and chimeric Alu/Alu sequences were formed at the
junctions (Figure S5). Among the 20 junctions without
extended homologies, 11 junctions (50.0%) had microho-
mologies (1–5 bp) andnine junctions (40.9%)werewithout
extended homologies or microhomologies, of which eight
had inserted sequences (1–19 bp). Importantly, theseell Lines) DMD (Germ Cell Lines) DMD (Cancer Cell Lines)
N % N %
% 2 1.0% 0 0.0%
% 0 0.0% 0 0.0%
% 0 0.0% 0 0.0%
% 1 0.5% 0 0.0%
% 4 2.0% 0 0.0%
% 6 3.0% 1 16.7%
6% 14 7.1% 1 16.7%
5% 33 16.8% 0 0.0%
% 30 15.2% 1 16.7%
6% 40 20.3% 0 0.0%
4% 128 65.0% 3 50.0%
% 1 0.5% 0 0.0%
0% 51 25.9% 2 33.3%
% 15 7.6% 1 16.7%
5% 67 34.0% 3 50.0%
junction-sequence signatures are similar to those of not
recurrently observed breakpoints, as described above.
Breakpoint-Clustering Regions Are Associated with
Multiple Factors Affecting Replication Timing
The breakpoint-clustering region in PARK2 in patients with
AR-JP coincided with the center of FRA6E, and the break-
point-clustering region in DMD in patients with DMD/
BMD was fully embedded in FRAXC (Figure 2), strongly
suggesting that the clustering of the breakpoints is closely
related to the mechanisms underlying fragility within the
CFSs. Although the mechanisms underlying CFS breakage
are still unclear, several factors that may contribute to
instability at CFSs have been suggested, including late-
replicating regions,13,14,30,31 high-ﬂexibility peaks,32,33
regions rich in nuclear-matrix-attachment regions,32,34,35
and regions located at the interface of G and R bands.36
On the basis of these reports, breakpoint-clustering regions
in PARK2 and DMD were analyzed for investigation of the
association of these regions with sequence motifs, replica-
tion timing, ﬂexibility peaks, nuclear-matrix-attachment
regions, and R/G bands. In addition, because there has
been a recent report suggesting that a deletion hotspot in
PARK2 in patients with AR-JP is associated with a meiotic
recombination hotspot,16 breakpoint-clustering regions
in PARK2 and DMD were also compared with the deCODE
recombination maps.28
We performed a systematic search for 40 different
sequence motifs previously associated with DNA breakage
using the DNA Pattern Find program to detect sequence
motifs reportedly abundant at breakpoints.23 For this
search, nucleotide sequences of 200 bp surrounding break-
points (referred to as a breakpoint region) and 5000
sequences of 200 bp (control sequences) randomly picked
from the entire PARK2 and DMD regions were used. Of the
40 sequence motifs, none were overrepresented in the
breakpoint regions (Table S2). On the basis of a recent
study of a replication-timing map of chromosome 6,27
it was found that one of the latest-replication regions
(S phase DNA to G1 phase DNA ratios of less than 1.2)
was chromosome 6: 161,884,878–162,579,873, which
coincided with the breakpoint-clustering region in PARK2
(Figure 3B). Because there were no reports of replication
timing of chromosome X, we were unable to investigate
the association of the breakpoint-clustering region in
DMD with replication timing. For investigation of ﬂexi-
bility peaks, chromosome 6: 162,370,000–162,870,000
and chromosome X: 31,500,000–32,000,000, correspond-
ing to the breakpoint-clustering regions in PARK2 and
DMD, respectively, and the neighboring regions (chromo-
some 6: 159,870,000–165,370,000 and chromosome X:
29,000,000–34,500,000) were analyzed in terms of AT
content, average twist angle, and numbers of ﬂexibility
peaks, uniﬁed peaks, and cluster of peaks (Table S3).
Although there were 25 ﬂexibility peaks in the break-
point-clustering regions in PARK2 and 26 ﬂexibility peaks
in the breakpoint-clustering regions in DMD, both ofThwhich were not overrepresented (50 peaks/Mb and 52
peaks/Mb) as compared with their neighboring region,
there were regions with high AT content (AT repeats)
near the breakpoint-clustering region (Figure 3C). Further-
more, the highest-ﬂexibility peaks with a twist angle of
more than 15.5 evidently ﬂanked the breakpoint-clus-
tering region (Figure 3D). On the high-resolution map of
the LADs,26 it was revealed that PARK2 and DMD were
embedded in large LADs (chromosome 6:161,789,694–
163,646,839 and chromosome X: 31,589,326–34,513,
733) (Figure 3E). This prompted us to investigate the rela-
tionships of LADs with other CFS genes, including FHIT,
WWOX, GRID2, LARGE, CTNNA3, NBEA, and CNTNAP2.
Intriguingly, all the CFS genes were embedded in large
LADs spanning several Mb (approximately 1.7–4.7 Mb).
Representative CFS genes are shown in Figure S6. The
intron 55 ofDMD spans the boundary of the chromosomal
R/G band: Xp21.2 (G band) to Xp21.1 (R band).25 The
breakpoint-clustering region in DMD was ﬂanked by the
boundary of the R/G band and was exclusively in the R
band, whose AT content was relatively high. In contrast,
there were neither obvious boundaries of the R/G band
nor signiﬁcant changes in AT content within PARK2
(Figure 3F). With the use of the deCODE map, the meiotic
recombination rate of the breakpoint-clustering regions
in PARK2 (D6S955 to D6S1599) was found to be high
(5.0 cM/Mb), as previously reported.16 The recombination
rate of the region covering the breakpoint-clustering
regions in DMD (DXS1214 to DXS1219) was also higher
(2.80 cM/Mb) than the average recombination rate along
chromosome X (1.14 cM/Mb), but was similar to those of
other regions in DMD (Figure 3G).Discussion
We have shown that a locus-speciﬁc high-density array
CGH analysis system is highly efﬁcient for beginning to
localize the exact breakpoints in genomic DNAs in germ
cell lines as well as in cancer cell lines. Utilizing this system
has enabled us to acquire data on approximately 500
breakpoint junctions involving PARK2 and DMD and to
investigate the various breakpoint-sequence features. This
study is applied to identifying such a large number of rear-
rangements at the nucleotide level. The high frequencies
of somatic rearrangements observed in cancer cell lines
(42 rearrangements in 125 cancer cell lines in PARK2 and
nine rearrangements in 125 cancer cell lines in DMD)
and the various independent rearrangements for germ
cell line rearrangements (140 of the 252 rearrangements
in PARK2 and 197 of the 197 rearrangements in DMD)
demonstrated how vulnerable these regions are for rear-
rangements. The difference in the frequency of somatic
rearrangements between PARK2 and DMD may be consis-
tent with the relative instability within these two loci:
PARK is within one of the most active CFSs,37 whereas
DMD is in a very low-expressing CFS.7e American Journal of Human Genetics 87, 75–89, July 9, 2010 83
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Figure 3. Association of Breakpoint-Clustering Regions in PARK2 and DMD with Replication Timing, Flexibility Peak, R/G Band, and
AT Content
(A) Histograms of positional distributions of breakpoints in PARK2 and DMD in germ cell lines. Breakpoint-clustering regions are the
regions with high frequencies (70%–78%) shown by arrows. The physical positions of PARK2, DMD, and the center of FRA6E are shown
below.
(B) Late-replicating regions,27 deﬁned as S to G1 DNA ratios of 1.1–1.2.
(C) Distributions of AT content (calculated with an average span of 500 bp and an average step of 100 bp).
(D) Distributions of ﬂexibility peaks of more than 13.7 in twist angle and more than 100 bp in length. Red bars are the highest peaks
whose twist angles exceed 15.5.
(E) Physical positions of LADs in PARK2 and DMD.26
(F) Chromosomal R and G bands are indicated by open and shaded boxes, respectively.
(G) Recombination rates based on the deCODE map.28Microhomologies Are Predominantly Involved
in Rearrangement Processes at CFSs in Germ Cell
and Somatic Cell Mutations
The present study demonstrated that microhomologies
were notably frequent (59.9% in PARK2 in patients with
AR-JP, 59.4% in PARK2 in cancer cell lines, 65.0% in
DMD in patients with DMD/BMD, and 50.0% in DMD in
cancer cell lines) at the junctions, strongly raising the
possibility that the rearrangements are predominantly
generated by mechanisms mediated by microhomologies
(Table 4, Figures 4Aa and 4Ab). Note that there are similarly
high frequencies of microhomologies in PARK2 rearrange-
ments in germ cell and cancer cell lines, which further
supports the notion that a common mechanism underlies
the generations of rearrangements in germ cell and cancer
cell lines. Consistent with our ﬁndings, microhomologies
at junctions have recently been observed in the rearrange-
ments of human culture cells experimentally induced by
aphidicolin, a model of CFS.38 Taken together, the present84 The American Journal of Human Genetics 87, 75–89, July 9, 2010ﬁndings strongly support the concept that the mecha-
nisms mediated by microhomologies play a major role
in rearrangement processes within CFSs (Figure 4A). In
contrast, rearrangements that can be explained by the
homology-dependent nonallelic homologous recombina-
tion (NAHR) are relatively rare, because there is only
a limited number of rearrangements (4.3% in PARK2 in
patients with AR-JP, 3.1% in PARK2 in cancer cell lines,
1.0% in DMD in patients with DMD/BMD, 0.0% in DMD
in cancer cell lines) whose junctions show extended
homologies (repetitive sequences) (Table 4, Figures 4Aa
and 4Ac). Considering the observation that multiple inde-
pendent rearrangements had frequently occurred in PARK2
and DMD, it is in a striking contrast to other common
genomic disorders, such as Charcot-Marie-Tooth disease
type 1A39 or Smith-Magenis syndrome,40 whose recurrent
mutations are characterized by homologous recombina-
tion and unequal crossing over between the ﬂanking
repeat elements.
A Microhomology-mediated repair mechanism is predominantly involved in rearrangement processes at CFSs
a) Properties of breakpoint junctions
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Figure 4. Schematic Representations of Mechanisms Underlying CFSs
(A) Themicrohomology-mediatedmechanism is predominantly involved in rearrangement processes at CFSs. (a) Detailed analysis of the
nucleotide-sequence content ﬂanking the breakpoints demonstrated that junctions with microhomologies (pink) are predominantly
observed, compared with junctions without any homology (sky blue). Junctions with extended homologies (green) underlying
NAHR are infrequent. (b) Schematic representation of MMEJ. (c) Schematic representation of NAHR.
(B) Multiple factors affecting DNA-replication kinetics collectively contribute to fragility as a common molecular basis. The breakpoint-
clustering region at CFSs is ﬂanked by the high-ﬂexibility peaks and the R/G band boundaries. The breakpoint-clustering region coin-
cides with the late-replicating region and is embedded in large LADs.Various mechanisms of rearrangement processes that
can result in microhomologies at junctions have been
proposed, which include nonhomologous end joining
(NHEJ), microhomology-mediated end joining (MMEJ),
microhomology-mediated break-induced replication
(MMBIR), and/or fork stalling and template switching
(FoSTeS). In eukaryotes, NHEJ is the major repair pathway
of DNA double-strand breaks, which functions by ligating
the two ends together.41 It has the potential to ligate any
type of double-strand break end without the requirement
for an extended homology. Even when starting with two
identical DNA ends, NHEJ is a highly ﬂexible process
accounting for the diverse breakpoint junctions, with
some ends showing short microhomologies (usually
1–4 bp) and some ends showing inserted sequences
without microhomologies.41 In addition, it was shown
that replication stress leads to the focus formation of key
components of the NHEJ pathway (Rad51 and DNA-
PKcs) colocalized with markers of DNA double-strand
breaks (MDC1 and gamma H2AX), and the downregula-
tion of the component of the NHEJ pathway (Rad 51,ThDNA-PKcs, or DNA ligase 4) leads to a signiﬁcant increase
in gaps and breaks at CFSs.42
MMEJ is another distinctive pathway of end-joining
repair, which requires microhomologies of terminal ends,
in contrast to NHEJ. High frequencies of microhomologies
at junctions (60%–65%) observed in this study would
favor the involvement of MMEJ at CFSs. Recently, the
MMBIR and/or FoSTeSmodel with emphasis on replication
fork collapse and/or stalling has also been proposed to
explain the origin of rearrangements on the basis of the
ﬁndings of complex rearrangements and junction
sequences showing microhomologies of 2–5 bp.43 Because
delayed replication at CFSs has been implicated to
underlie the rearrangements involving CFSs, MMBIR/
FoSTeS deserves serious consideration as a possible mecha-
nism underlying the rearrangements at CFSs. Actually, we
observed a case of complex rearrangements in DMD
comprising short tandemmultiplications followed by large
deletions (Figure 5), which strongly supports the involve-
ment of multiple MMBIR/FoSTeS events, at least in this
case. For other cases, however, it is difﬁcult to deduce, one American Journal of Human Genetics 87, 75–89, July 9, 2010 85
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Figure 5. Complex Rearrangements in DMD Considered to be Generated by MMBIR/FoSTeS Observed in One Patient with DMD
An example of complex rearrangements in DMD with microhomology junctions leading to the deletion of approximately 5.7 kb,
including exon 12 of DMD, is shown.
(A) A map of a part of DMD. The colored boxes represent blocks of sequences.
(B) A hypothetical series of four template switches leading to rearrangements, indicated by gray curved arrows and numbers; a gray
curved arrow indicates resumption of replication on the original template. Numbers corresponding to the sequences are shown in (C).
(C) Rearranged chromosomal region, in which tandemmultiplications connect the green sequence to the brown sequence (1), the pink
sequence to the brown sequence (2), and the tan sequence to the pink sequence (3), followed by gross deletion between the sky blue
sequence and the purple sequence (4). The nucleotide sequences of the colored segments correspond to the colored boxes in (A), (B),
and (C). The red boxes indicate the sequences of microhomologies. The gray box represents the inserted sequence of a junction. (1)
The junction between the green and the brown sequences shows a 1 bp microhomology. (2) The junction between the pink and the
brown sequences shows a 6 bpmicrohomology. (3) The junction between the tan and the pink sequences shows a 5 bp inserted sequence
without microhomology. (4) The junction between the sky blue and the purple sequences shows a 2 bpmicrohomology. The sizes of the
brown, pink, tan, sky blue, and green fragments are 4, 10, 5, 41, and 2 bp, respectively, including the microhomology sequences at both
ends.the basis of breakpoint sequences, whether a replication-
based repair mechanism (MMBIR/FoSTeS) is commonly
involved in the generation of rearrangements.
Associations of Breakpoint-Clustering Regions
in CFSs with DNA Replication Kinetics
In this study, we found that regionswhere breakpoints clus-
tered within CFSs coincided with latest-replicating regions
and demonstrated that the highest-ﬂexibility peaks and
R/G band boundary ﬂanked a breakpoint-clustering region
(Figure 3). The highest-ﬂexibility peaks44 and R/G band
boundary45 are considered to affect replication timing.
Interestingly, we observed that PARK2 and DMD are
embedded in large LADs and furthermore found the coloc-
alizations of other CFS genes, including FHIT, WWOX,
GRID2, LARGE, CTNNA3, NBEA, and CNTNAP2, with large
LADs (Figure 3E and Figure S6). It was reported that 1344
LADs are aligned on the human genome, comprising
approximately 40% of the entire human genome.26 In86 The American Journal of Human Genetics 87, 75–89, July 9, 2010higher eukaryotic cells, DNA is organized into loops
attached to the nuclear matrix. Each loop represents one
individual replicon, with the ends of the replicon attached
to thenuclearmatrix at the bases of the loop.Upon comple-
tion of replication of any replicon, the resulting entangled
loops of the newly synthesized DNA are resolved by topoi-
somerase II present in the nuclear matrix, which generate
double-strand breaks with the potential risk leading to
vulnerability for rearrangements.46 Because LADs comprise
approximately 40% of the human genome, as described
above, association of CFSswith large LADs does not directly
explain the rearrangement clustering of CFSs. Further
cytogenetic investigations should be conducted to explore
whether LADs are associated with intrinsic replication
difﬁculties in CFSs. It has been shown that recombination
rates are relatively high in the regions covering the
breakpoint-clustering regions, which may indicate a possi-
bility that genomic instabilities also contribute to meiotic
recombination (Figure 3G). In summary, our ﬁndings
suggest that multiple factors affecting DNA-replication
timing collectively contribute to the vulnerability for rear-
rangements, which include high-ﬂexibility peaks, R/G
band boundary, and large LADs (Figure 4B). These factors
cause substantial difﬁculties in replication machineries,
and CFSs represent unreplicated regions of the genome
that have escaped the replication checkpoints and are
visible as gaps and breaks on metaphase chromosomes.Involvement of CFSs with Rearrangements
in Germlines Leading to Human Diseases
To date, several lines of evidence have demonstrated that
somatic rearrangements that occur within CFSs are associ-
ated with cancer development,47,48 but CFSs have rarely
drawn attention as genomic structures associated with
germline rearrangements. This study provides evidence
that chromosomal instability associated with CFSs plays
an important role in gross deletions and duplications in
germ cell lines leading to human diseases. Recently,
numerous CNVs in the human genome have been identi-
ﬁed in control subjects via various platforms, including
array CGH, SNP genotyping, and next-generation
sequencing.49–52 Because sample-selection bias inevitably
affects the distributions of germline rearrangements, unbi-
ased knowledge about CNVs distributions will also be
needed to explore whether the common mechanism can
underlie CFSs. Such investigations will certainly be essen-
tial for better understanding the molecular basis of CFSs
and human diseases associated with instabilities in the
human genome.Supplemental Data
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